CONTROLLED RELEASE PARENTERAL DELIVERY SYSTEM

控释肠外给药系统

• 批准号: 2664204
• 负责人: RAM B. MURTY
• 金额: $ 75.02万
• 依托单位: MURTY PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/2664204
• 关键词: buprenorphine; dosage forms; drug addiction antagonist; drug delivery systems; drug design /synthesis /production; slow release drug

A major program of the National Institute on Drug Abuse (NIDA) is to develop new pharmacotherapeutics for the treatment of drug addiction. Controlled-release preparations which maintain an effective drug concentration for a long period of time and therefore alleviate the need for frequent drug administration offer advantages over conventional dosage forms. Such preparations are particularly useful in the treatment of drug addiction, because long-term treatment is usually required and patient compliance can be a problem. In addition, sustained-release preparations for the treatment of narcotic addiction could help maximize the existing treatment resources, an issue of increasing importance in view of the concern over the role of intravenous drug abusers in the AIDS epidemic. The purpose of this contract is to develop a clinically useful controlled- release preparation to provide buprenorphine effects for an extended period of time. Buprenorphine is a partial opioid agonist and has been shown to be effective for the treatment of opioid dependence. During the phase I period of the contract, several different microsphere formulations of buprenorphine have been prepared and characterized. The feasibility of developing a controlled-release buprenorphine delivery system has been demonstrated. During the phase II period, the contractor will continue to develop a parental delivery system of buprenorphine suitable for clinical use.

国家药物滥用研究所（NIDA）的一个主要项目是 开发新的药物治疗药物以治疗毒瘾。 保持有效药物的控释制剂 长时间的集中，因此减轻了需要 对于频繁给药， 剂型。 这样的制剂特别适用于 药物成瘾的治疗，因为长期治疗通常是 患者的依从性可能是一个问题。 此外，本发明还提供了一种方法， 用于治疗麻醉剂成瘾的缓释制剂 可以帮助最大限度地利用现有的治疗资源， 鉴于对作用的担忧，其重要性日益增加 艾滋病流行中的静脉注射吸毒者。 本合同的目的是开发一种临床上有用的受控- 提供丁丙诺啡作用的缓释制剂 段时间 丁丙诺啡是一种部分阿片类激动剂， 对治疗阿片类药物依赖有效。 期间 第一阶段合同期内，几种不同的微球 已经制备并表征了丁丙诺啡的制剂。 丁丙诺啡控释制剂的可行性研究 系统已经得到验证。 在第二阶段期间， 承包商将继续开发一个父母交付系统， 丁丙诺啡适合临床使用。